ArQule (NASDAQ:ARQL) +35.9% pre-market after releasing preliminary results from its phase 1 dose escalation study for ARQ 531 demonstrates substantial anti-tumor activity and a favorable safety profile.
Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a partial response, according to results delivered at the 2019 European Hematology Association meeting in Amsterdam.
ARQL says it is “now focused on finalizing the recommended phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.